327 related articles for article (PubMed ID: 24947930)
1. Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts.
Cottu P; Bièche I; Assayag F; El Botty R; Chateau-Joubert S; Thuleau A; Bagarre T; Albaud B; Rapinat A; Gentien D; de la Grange P; Sibut V; Vacher S; Hatem R; Servely JL; Fontaine JJ; Decaudin D; Pierga JY; Roman-Roman S; Marangoni E
Clin Cancer Res; 2014 Aug; 20(16):4314-25. PubMed ID: 24947930
[TBL] [Abstract][Full Text] [Related]
2. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
3. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
Creighton CJ; Massarweh S; Huang S; Tsimelzon A; Hilsenbeck SG; Osborne CK; Shou J; Malorni L; Schiff R
Cancer Res; 2008 Sep; 68(18):7493-501. PubMed ID: 18794137
[TBL] [Abstract][Full Text] [Related]
4. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells.
Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH
BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787
[TBL] [Abstract][Full Text] [Related]
6. A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers.
Parra-Palau JL; Pedersen K; Peg V; Scaltriti M; Angelini PD; Escorihuela M; Mancilla S; Sánchez Pla A; Ramón Y Cajal S; Baselga J; Arribas J
Cancer Res; 2010 Nov; 70(21):8537-46. PubMed ID: 20978202
[TBL] [Abstract][Full Text] [Related]
7. HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression.
Shah N; Jin K; Cruz LA; Park S; Sadik H; Cho S; Goswami CP; Nakshatri H; Gupta R; Chang HY; Zhang Z; Cimino-Mathews A; Cope L; Umbricht C; Sukumar S
Cancer Res; 2013 Sep; 73(17):5449-58. PubMed ID: 23832664
[TBL] [Abstract][Full Text] [Related]
8. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC
Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335
[TBL] [Abstract][Full Text] [Related]
9. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
10. p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.
Fernandez-Cuesta L; Anaganti S; Hainaut P; Olivier M
Int J Cancer; 2011 Apr; 128(8):1813-21. PubMed ID: 20549698
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.
Hiscox S; Baruha B; Smith C; Bellerby R; Goddard L; Jordan N; Poghosyan Z; Nicholson RI; Barrett-Lee P; Gee J
BMC Cancer; 2012 Oct; 12():458. PubMed ID: 23039365
[TBL] [Abstract][Full Text] [Related]
13. Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP.
Piggott L; Silva A; Robinson T; Santiago-Gómez A; Simões BM; Becker M; Fichtner I; Andera L; Young P; Morris C; Barrett-Lee P; Alchami F; Piva M; Vivanco MD; Clarke RB; Gee J; Clarkson R
Clin Cancer Res; 2018 May; 24(10):2452-2463. PubMed ID: 29363524
[No Abstract] [Full Text] [Related]
14. Harmful effect of ERβ on BCRP-mediated drug resistance and cell proliferation in ERα/PR-negative breast cancer.
Li W; Jia M; Qin X; Hu J; Zhang X; Zhou G
FEBS J; 2013 Dec; 280(23):6128-40. PubMed ID: 24103091
[TBL] [Abstract][Full Text] [Related]
15. Expression of the CD59 Glycoprotein Precursor is Upregulated in an Estrogen Receptor-alpha (ER-α)-Negative and a Tamoxifen-Resistant Breast Cancer Cell Line In Vitro.
Xiong H; Jin X; You C
Med Sci Monit; 2018 Nov; 24():7883-7890. PubMed ID: 30391994
[TBL] [Abstract][Full Text] [Related]
16. Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance.
Dabydeen SA; Kang K; Díaz-Cruz ES; Alamri A; Axelrod ML; Bouker KB; Al-Kharboosh R; Clarke R; Hennighausen L; Furth PA
Carcinogenesis; 2015 Jan; 36(1):122-32. PubMed ID: 25421723
[TBL] [Abstract][Full Text] [Related]
17. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2.
Pancholi S; Lykkesfeldt AE; Hilmi C; Banerjee S; Leary A; Drury S; Johnston S; Dowsett M; Martin LA
Endocr Relat Cancer; 2008 Dec; 15(4):985-1002. PubMed ID: 18824559
[TBL] [Abstract][Full Text] [Related]
18. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
[TBL] [Abstract][Full Text] [Related]
19. A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1.
Ming J; Ruan S; Wang M; Ye D; Fan N; Meng Q; Tian B; Huang T
Oncotarget; 2015 Dec; 6(38):40692-703. PubMed ID: 26517687
[TBL] [Abstract][Full Text] [Related]
20. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.
Ramaswamy B; Lu Y; Teng KY; Nuovo G; Li X; Shapiro CL; Majumder S
Cancer Res; 2012 Oct; 72(19):5048-59. PubMed ID: 22875023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
